Terms: = Gastric cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
1259 results:
1. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
Zhao Y; Li D; Zhuang J; Li Z; Xia Q; Li Z; Yu J; Wang J; Zhang Y; Li K; Xu S; Li S; Ma P; Cao Y; Liu C; Xu C; Liu Z; Wei J; Zhang C; Qiao L; Gao X; Hou Z; Liu C; Zheng R; Wang D; Liu Y
Clin Transl Med; 2024 May; 14(5):e1674. PubMed ID: 38685486
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
[TBL] [Abstract] [Full Text] [Related]
3. [A Case of Advanced gastric cancer Treated with Conversion Surgery followed by Nivolumab Combination Chemotherapy].
Sekino N; Natsume T; Tanaka H; Kainuma O; Sato Y; Note H; Yoshioka T; Kamata T; Odera H; Uchiyama M; Maruyama T; Takahashi H; Hirano S
Gan To Kagaku Ryoho; 2024 Apr; 51(4):417-420. PubMed ID: 38644309
[TBL] [Abstract] [Full Text] [Related]
4. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
5. Phenotypic immune characterization of gastric and esophageal adenocarcinomas reveals profound immune suppression in esophageal tumor locations.
Groen-van Schooten TS; Harrasser M; Seidel J; Bos EN; Fleitas T; van Mourik M; Pouw RE; Goedegebuure RSA; Doeve BH; Sanders J; Bos J; van Berge Henegouwen MI; Thijssen VLJL; van Grieken NCT; van Laarhoven HWM; de Gruijl TD; Derks S
Front Immunol; 2024; 15():1372272. PubMed ID: 38638445
[TBL] [Abstract] [Full Text] [Related]
6. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
7. her2 targeted therapy in colorectal cancer: Current landscape and future directions.
Chen N; He L; Zou Q; Deng H
Biochem Pharmacol; 2024 May; 223():116101. PubMed ID: 38442793
[TBL] [Abstract] [Full Text] [Related]
8. The role of mir96 in predicting CTC status and prognostic evaluation in gastric cancer patients.
Zheng Q; Ge H
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):264-274. PubMed ID: 38430012
[TBL] [Abstract] [Full Text] [Related]
9. Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study.
Demirci NS; Azizy A; Paksoy N; Doğan İ; Karabulut S; Karahan L; Tastekin D
Medicine (Baltimore); 2024 Mar; 103(9):e37259. PubMed ID: 38428877
[TBL] [Abstract] [Full Text] [Related]
10. Advances in targeted therapy for gastric cancer based on tumor driver genes.
Wu S; Xu P; Zhang F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 53(1):73-83. PubMed ID: 38413217
[TBL] [Abstract] [Full Text] [Related]
11. her2
Hu HH; Wang SQ; Zhao H; Chen ZS; Shi X; Chen XB
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38391024
[TBL] [Abstract] [Full Text] [Related]
12. Elucidating molecular mechanisms and therapeutic synergy: irreversible her2-TKI plus T-Dxd for enhanced anti-her2 treatment of gastric cancer.
Liu J; Zhu T; Zhao R; Ren W; Zhao F; Liu J
Gastric Cancer; 2024 May; 27(3):495-505. PubMed ID: 38386239
[TBL] [Abstract] [Full Text] [Related]
13. Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes.
Baccili Cury Megid T; Baskurt Z; Ma LX; Barron CC; Farooq A; Saltiel MP; Wang X; Bach Y; Ayoama H; Jang RW; Chen E; Veit-Haibach P; Wang B; Kalimuthu S; Cotton J; Wong R; Mesci A; Elimova E
J Neurooncol; 2024 Mar; 167(1):111-122. PubMed ID: 38372902
[TBL] [Abstract] [Full Text] [Related]
14. Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer.
Chang L; Zhang X; Ma Q; Kong L; Yu Y; Tao J; Li Q
Invest New Drugs; 2024 Apr; 42(2):161-170. PubMed ID: 38367168
[TBL] [Abstract] [Full Text] [Related]
15. Combination treatment with anti-her2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report.
Liu Z; Wang F; Zhang Y; Lu J; Yang Y
Front Immunol; 2024; 15():1321946. PubMed ID: 38361930
[TBL] [Abstract] [Full Text] [Related]
16. miRNA-449c-5p regulates the JAK-STAT pathway in inhibiting cell proliferation and invasion in human breast cancer cells by targeting erbb2.
Li L; Zhang Y; Yang K; Liu W; Zhou Z; Xu Y
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1974. PubMed ID: 38351535
[TBL] [Abstract] [Full Text] [Related]
17. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Gou M; Zhang Y; Wang Z; Qian N; Dai G
Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
[TBL] [Abstract] [Full Text] [Related]
18. Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for her2-positive tumors.
Zhao S; Qiu Y; Yuan M; Wang Z
Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
[TBL] [Abstract] [Full Text] [Related]
19. Cdc42-driven endosomal cholesterol transport promotes collateral resistance in her2-positive gastric cancer.
Liang B; Wu Q; Wang Y; Shi Y; Sun F; Huang Q; Li G; Liu Y; Zhang S; Xu X; Yao G; Peng J; Zhai X; Wu J; Tan Y; Wu Z; Zhou R; Li S; Wu J; Yang M; Liao W; Shi M
Cancer Lett; 2024 Apr; 587():216702. PubMed ID: 38336288
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with her2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
Li N; Li Z; Fu Q; Zhang B; Zhang J; Wan XB; Lu CM; Wang JB; Deng WY; Ma YJ; Bie LY; Wang MY; Li J; Xia QX; Wei C; Luo SX
Int J Surg; 2024 Apr; 110(4):2071-2084. PubMed ID: 38320099
[TBL] [Abstract] [Full Text] [Related]
[Next]
